Navigation Links
Celsion Reports Third Quarter 2010 Financial Results and Provides Business Update
Date:11/15/2010

er of 2010, Celsion recorded as other income a $0.5 million non-cash benefit related to a mark-to-market change in the common stock warrant liability related to the stock offering completed in September 2009.  In the first nine months of 2010, Celsion recorded a $0.7 million non-cash benefit related to the change in the common stock warrant liability.  In the same period of 2009, the Company recorded a non-cash indemnity reserve benefit of $1.1 million related to the sale of its medical device business in 2007, which reduced general and administrative expenses in the nine month prior year period.

The Company ended the third quarter with $3.2 million of cash and investments.  In September 2010, the Company raised $1.4 million from two draws under its June 2010 Committed Equity Financing Facility.  The proceeds will be used to accelerate commercial manufacturing activities for ThermoDox®.  On November 1, 2010, the Company was awarded a $244,000 grant under the Qualifying Therapeutic Discovery Project (QTDP) program under The Patient Protection and Affordable Care Act of 2010. This maximum grant amount for a single program was awarded to Celsion for its Thermodox® clinical development program.

Recent Business Highlights

  • Patient enrollment for the Phase III HEAT study to date is approaching 80% completion.  Efforts to stimulate patient enrollment continue with full enrollment expected in the first quarter of 2011;
  • The Committee for Orphan Medicinal Products of the European Medicines Agency (EMA) issued a positive opinion on the Company's application for Orphan Drug Designation for ThermoDox® for the treatment of HCC;
  • The Independent Data Monitoring Committee unanimously recommended continuation of the Phase III HEAT study to treat Primary Liver Cancer after review of 401 patients enrolled in the trial;
  • Fast Track designation received for ThermoDox® development program
    '/>"/>

  • SOURCE Celsion Corporation
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6

    Related biology technology :

    1. Celsion Announces Date and Time Change for Third Quarter 2010 Financial Results Conference Call to Monday, November 15, 2010
    2. SCOLR Pharma, Inc. Reports Second Quarter 2008 Financial Results
    3. AutoImmune Inc. Reports 2008 Second Quarter Financial Results
    4. Par Pharmaceutical Reports Second Quarter 2008 Results
    5. ISTA Pharmaceuticals Reports Second Quarter 2008 Financial Results
    6. Pharmos Corporation Reports 2008 Second Quarter Results
    7. Halozyme Therapeutics Reports 2008 Second Quarter Financial Results
    8. MGT Capital Investments Reports Second Quarter 2008 Financial Results and Provides Update on Recent Developments
    9. BMP Sunstone Reports Second Quarter 2008 Financial Results
    10. ULURU Inc. Reports Second Quarter 2008 Financial Results
    11. Immtech Reports Fiscal First Quarter 2009 Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:4/1/2015)... (PRWEB) April 01, 2015 The concept of ... a multi-billion dollar industry. Founder of Fasciology, Ashley Black, says ... area of fat, instead of having to wait for the ... claims that “ prior to fat cooling procedures, the ... or contouring, was liposuction, which is a highly invasive procedure.” ...
    (Date:4/1/2015)... 2015 National recruitment firm Slone ... Brad Allen as Head of Sales at Optimal Medicine, ... market. , Allen brings over 20 years experience ... a number of companies including Dell Services Healthcare, Medsphere ... were a perfect fit for accomplishing the goals Optimal ...
    (Date:3/31/2015)... JUNCTION, N.J., March 31, 2015 CytoSorbents ... company using blood purification to treat critically-ill and ... an operational summary and reports financial results for ... 2014 CytoSorb® product revenues were a ... compared to 2013 CytoSorb® revenues of $0.8M Highlights ...
    (Date:3/31/2015)... VANCOUVER , March 31, 2015  /PRNewswire/ - ESSA Pharma ... that it has filed with the Food and Drug ... ("IND") application related to the Company,s proposed clinical trial ... IND application is required in order for ESSA to ... The IND application is a complete description ...
    Breaking Biology Technology:Hybrid Health Guru, Ashley Black, announces that her invention The FasciaBlaster™ rivals the “fat cooling” procedures that reduce exercise and diet resistant fat pockets. 2Hybrid Health Guru, Ashley Black, announces that her invention The FasciaBlaster™ rivals the “fat cooling” procedures that reduce exercise and diet resistant fat pockets. 3Slone Partners Fills Head of Sales at Optimal Medicine 2CytoSorbents Reports Record 2014 Revenue 2CytoSorbents Reports Record 2014 Revenue 3CytoSorbents Reports Record 2014 Revenue 4CytoSorbents Reports Record 2014 Revenue 5CytoSorbents Reports Record 2014 Revenue 6CytoSorbents Reports Record 2014 Revenue 7CytoSorbents Reports Record 2014 Revenue 8CytoSorbents Reports Record 2014 Revenue 9CytoSorbents Reports Record 2014 Revenue 10CytoSorbents Reports Record 2014 Revenue 11ESSA Pharma Inc. Announces Filing of Investigational New Drug Application for EPI-506 2ESSA Pharma Inc. Announces Filing of Investigational New Drug Application for EPI-506 3ESSA Pharma Inc. Announces Filing of Investigational New Drug Application for EPI-506 4
    ... Mass., March 3 ETEX Corporation, an advanced,biomaterials ... a supply,agreement with LifeNet Health, Inc., Under ... Bone Matrix (DBM) powder to be mixed with ... substitute material called,EquivaBone(TM). ETEX will manufacture EquivaBone(TM) in ...
    ... Md., March 3 Iomai Corporation,(Nasdaq: IOMI ) ... 2007 financial results before the markets open and hold ... clinical progress,on Thursday, March 6, 2008 at 1:30 p.m. ... the live conference call on Thursday, March 6 at ...
    ... - BIKAM,pioneers in the discovery and development ... degenerative eye diseases and ocular disorders and,Dalton ... worldwide,collaboration and agreement to discover and develop ... Dalton Medicinal Chemistry will utilize their proprietary ...
    Cached Biology Technology:ETEX and LifeNet Health, Inc. Enter Agreement 2Iomai to Announce Fourth Quarter and Year-End 2007 Financial Results and Host Webcast on Thursday, March 6 2BIKAM and Dalton Medicinal Chemistry Sign Collaborative Research Agreement 2
    (Date:3/16/2015)... HANOVER, Germany , March 16, 2015 /PRNewswire/ ... DERMALOG Identification Systems GmbH will present groundbreaking innovations ... Hanover, Germany . ... DERMALOG,s latest biometric innovation is well at ... the next generation e-gate made in ...
    (Date:3/12/2015)... , March 12, 2015 The mascots ... Brenner Children,s Hospital, part of Wake Forest Baptist Medical ... initiative for the 2015 ACC Men,s Basketball Tournament. Young ... with them and getting their autographs. Brenner ... Baptist. It is the only children,s hospital in northwest ...
    (Date:3/12/2015)... Calif. , March 12, 2015 WHEN:Tuesday, ... Complimentary Registration here: http://bit.ly/1G7Os0L . SPEAKERS: , ... Aravind SeshagiriPhoto - http://photos.prnewswire.com/prnh/20150311/181111 ... order to compete in several different markets and ... is currently witnessing an uptrend. ...
    Breaking Biology News(10 mins):DERMALOG Presents its Latest Biometric Innovations at the Hannover CeBIT Exhibition, 16 - 20 March 2015 2DERMALOG Presents its Latest Biometric Innovations at the Hannover CeBIT Exhibition, 16 - 20 March 2015 3Biometrics Key to Future Growth in Healthcare, Retail and Financial Markets 2Biometrics Key to Future Growth in Healthcare, Retail and Financial Markets 3
    ... drugs of abuse decrease the generation of new neurons ... this process, called neurogenesis, had not been clear. , ... advance of print publication of the November issue of ... from University of Saskatchewan show that a potent and ...
    ... a type of blue-green algae known as Nostoc, shows promise ... other neurodegenerative diseases, according to an in vitro study by ... time that a potent agent against Alzheimer's has been isolated ... published in the Dec. 26 issue of the Journal ...
    ... that has been used to track the source of ... may have some new uses: detecting rapidly growing cancers ... known as "stable isotope ratio mass spectrometry," can determine ... or isotopes of an element in the substance ?such ...
    Cached Biology News:Natural compound from 'pond scum' shows potential activity against Alzheimer's 2War on terror meets war on cancer 2War on terror meets war on cancer 3War on terror meets war on cancer 4War on terror meets war on cancer 5War on terror meets war on cancer 6
    This antibody detects an ~92 kDa protein corresponding to the apparent molecular mass of the beta subunit of Hypoxia Inducible Factor-1 (HIF-1beta) on Western blots....
    Complexin-1/2 (FL-134)...
    ...
    ... Endothelin-1 (human, porcine) Endogenous ... endothelin ETA receptor and modulates vascular tonus. ... of three distinct endothelin genes. ET-2 and ... in two and six amino acids, respectively. ...
    Biology Products: